*ST Shuangcheng Co., Ltd.

Announcement on the Completion of Business Registration Changes and Obtaining Business License by Wholly-Owned Subsidiary of Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement on the Progress of Hainan Shuangcheng Pharmaceutical Co., Ltd.'s Application to Withdraw the Delisting Risk Warning

Legal Opinion from Beijing Zhonglun Law Firm on the 2025 Annual Shareholders' Meeting of Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement of the 2025 Annual Shareholders' Meeting Resolutions of Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement from Hainan Shuangcheng Pharmaceutical Co., Ltd. regarding participation in the 2025 annual report performance briefing and investor online collective reception day activities for listed companies in Hainan

Announcement on Holding the 2025 Online Performance Briefing by Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement of the Fourth Meeting Resolution of the Sixth Board of Directors of Hainan Shuangcheng Pharmaceutical Co., Ltd.

Q1 2026 Report

Announcement from Hainan Shuangcheng Pharmaceutical Co., Ltd. on Completion of Business Registration Changes and Obtaining Business License

Announcement from Hainan Shuangcheng Pharmaceutical Co., Ltd. on the Approval of ANDA for Injectable Pantoprazole Sodium by the US FDA

Announcement by Hainan Shuangcheng Pharmaceutical Co., Ltd. on the Completion of Business Registration Changes and Obtaining Business License by Its Controlling Subsidiary

Announcement on the Proposed Reappointment of the Accounting Firm by Hainan Shuangcheng Pharmaceutical Co., Ltd.

Special Explanation on Matters Related to the 2024 Audit Report Highlighting Matters with No Reservations by the Board of Directors of Hainan Shuangcheng Pharmaceutical Co., Ltd.

2025 Annual Work Report of the Board of Directors of Hainan Shuangcheng Pharmaceutical Co., Ltd.

Independent Director's 2025 Annual Work Report of Hainan Shuangcheng Pharmaceutical Co., Ltd. (Xiao Jianhua)

Independent Director's 2025 Annual Work Report of Hainan Shuangcheng Pharmaceutical Co., Ltd. (Li Jianwei)

Audit Report on Internal Control of Hainan Shuangcheng Pharmaceutical Co., Ltd. by the Accounting Firm

Internal Control Evaluation Report for 2025 by Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement on Uncovered Losses Reaching One-Third of Total Paid-in Capital by Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement on the 2025 Salary Situation and 2026 Salary Plan for Directors and Senior Management of Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement on Changes in Accounting Policies by Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement on Provision for Credit and Asset Impairment Losses by Hainan Shuangcheng Pharmaceutical Co., Ltd.

Notice of the 2025 Annual Shareholders' Meeting of Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement of Resolutions from the Third Meeting of the Sixth Board of Directors of Hainan Shuangcheng Pharmaceutical Co., Ltd.

Announcement on the Profit Distribution Plan for 2025 by Hainan Shuangcheng Pharmaceutical Co., Ltd.

Special Verification Report on Non-Recurring Gains and Losses of Hainan Shuangcheng Pharmaceutical Co., Ltd. by the Accounting Firm

Evaluation Report on the Accounting Firm's Performance for Hainan Shuangcheng Pharmaceutical Co., Ltd. in 2025

Report from the Audit Committee of Hainan Shuangcheng Pharmaceutical Co., Ltd. on the Accounting Firm's Supervision Duties for 2025